edited by Mark Bernstein, MD, and Mitchel S. Berger, MD, 496 pp, with illus, $169.95, ISBN 978-1-58890-497-3, New York, New York, Thieme, 2008.
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
Neuro-oncologists have witnessed dramatic improvements in our understanding of the biology and treatment of primary brain tumors. The management of patients with primary brain tumor has also improved with advances in neurosurgical and imaging techniques and the use of multimodal therapies. Integration of advanced imaging into surgical planning decreases patient morbidity, and maximal tumor resection is now recognized as playing a central role in improving the overall survival of patients with low- and high-grade gliomas. Since the publication of the first edition of Neuro-Oncology: The Essentials8 years ago, numerous advances have been made, including the discovery of the importance of glioma cancer stem cells; the molecular classification of glioma tumor subtypes, which may predict outcome; and the confirmation that chemotherapy unequivocally improves the survival of patients with malignant glioma. These advancements, to name only a few, are incorporated into the outstanding second edition of Neuro-Oncology: The Essentialsand highlight the objective of the editors to make the book an up-to-date reference for fundamental information.
Neuro-Oncology: The Essentials, 2nd ed. Arch Neurol. 2009;66(8):1042-1044. doi:10.1001/archneurol.2009.161